Danish pole position

Danish leads among life science stocks in the first half of the year

The first half of the year is over and it's time to swap the ergonomic office chair for a lounge chair. For us...

July 8
News roundup Monday, May 19

News roundup Wednesday April 5

The latest from BioStock

5th April 2023
The value of patent protection in life science

The value of patent protection in life science

Inventing, developing and launching new pharmaceuticals and medical devices is a long, capital-intensive and risky process. Ownership and...

December 14
Pila Pharma broadens its portfolio

Pila Pharma expands XEN-D0501 with new indication

Malmö-based Pila Pharma announced in the spring that it had applied for orphan drug status for the drug candidate XEN-D0501 for the treatment of erythromelalgia. In...

August 31
Pila Pharma's CEO on the Q2 report

Pila Pharma's CEO comments on the Q2 report

Malmö-based biotech company Pila Pharma is continuing steadily towards clinical phase II studies with XEN-D0501. In the second quarter of 2022...

August 30
Pila Pharma starts studies

Pila Pharma begins toxicological studies

The Malmö company Pila Pharma is in full swing with preparations for phase IIb studies with the drug candidate XEN-D0501. Before it can be started...

July 5
Deep dive into Pila Pharma's clinical concept

Deep dive into Pila Pharma's clinical concept

Type 2 diabetes is one of the most common diseases in the world. A company that wants to take a piece of the market pie...

25th of May 2022
Pila Pharma explores XEN-D0501 in pain management

Pila Pharma enters pain with XEN-D0501

After long having diabetes as the only track for the drug candidate XEN-D0501, Pila Pharma is now taking the next step on the journey...

29th April 2022
Dorte X Gram talks about the building of the company

Pila Pharma's CEO on company development since listing

"We're on our way". This is how the CEO's words begin when Pila Pharma's CEO Dorte X. Gram reports on the full year 2021 in the year-end report...

February 25
Pila Pharma reorganizes

Novo veteran strengthens Pila Pharma

The production of study material for XEN-D0501 is underway and is expected to be completed before the summer, after which Pila Pharma can begin...

February 10
Interest in life science listings remains high in 2021

Continued high interest in life science listings in 2021

After a successful year for life science on the stock market in 2020, the skyrocketing interest in the sector continued in 2021....

January 20
Pila Pharma expects several triggers in 2022

Several triggers for Pila Pharma in 2022

There is no doubt that type 2 diabetes has become one of the most common diseases with more than a...

January 19